자기자본비율 (ROE)
2005년부터
계산
Celgene Corp., ROE, 장기 추세계산
| ROE | = | 100 | × | Celgene에 귀속되는 순이익(손실)1 | ÷ | 주주의 자본1 | |
|---|---|---|---|---|---|---|---|
| 2018. 12. 31. | 65.67% | = | 100 | × | 4,046) | ÷ | 6,161) |
| 2017. 12. 31. | 42.48% | = | 100 | × | 2,940) | ÷ | 6,921) |
| 2016. 12. 31. | 30.29% | = | 100 | × | 1,999) | ÷ | 6,599) |
| 2015. 12. 31. | 27.07% | = | 100 | × | 1,602) | ÷ | 5,919) |
| 2014. 12. 31. | 30.65% | = | 100 | × | 2,000) | ÷ | 6,525) |
| 2013. 12. 31. | 25.94% | = | 100 | × | 1,450) | ÷ | 5,590) |
| 2012. 12. 31. | 25.57% | = | 100 | × | 1,456) | ÷ | 5,694) |
| 2011. 12. 31. | 23.91% | = | 100 | × | 1,318) | ÷ | 5,513) |
| 2010. 12. 31. | 14.71% | = | 100 | × | 881) | ÷ | 5,984) |
| 2009. 12. 31. | 17.68% | = | 100 | × | 777) | ÷ | 4,395) |
| 2008. 12. 31. | -43.93% | = | 100 | × | (1,534) | ÷ | 3,491) |
| 2007. 12. 31. | 7.96% | = | 100 | × | 226) | ÷ | 2,844) |
| 2006. 12. 31. | 3.49% | = | 100 | × | 69) | ÷ | 1,976) |
| 2005. 12. 31. | 10.01% | = | 100 | × | 64) | ÷ | 636) |
보고서 기준: 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
1 US$ 단위: 백만 달러
경쟁사와의 비교
Celgene Corp., ROE, 장기 추세, 경쟁사와의 비교
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018. 12. 31. | 65.67% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | -25.14% | 17.59% | 27.91% | 10.65% |
| 2017. 12. 31. | 42.48% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | — | 29.47% | 19.51% | 8.76% |
| 2016. 12. 31. | 30.29% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | — | 12.12% | 20.13% | 9.39% |
| 2015. 12. 31. | 27.07% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | — | 10.75% | 17.40% | 9.25% |
| 2014. 12. 31. | 30.65% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | — | 12.81% | 13.69% | 9.22% |
| 2013. 12. 31. | 25.94% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | — | 28.83% | 21.74% | 7.55% |
| 2012. 12. 31. | 25.57% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 11.63% | — | 17.93% | 60.24% | 7.62% |
| 2011. 12. 31. | 23.91% | — | 19.35% | 23.25% | 12.85% | 32.11% | 41.60% | 16.94% | 11.50% | — | 12.18% | -45.65% | 8.84% |
| 2010. 12. 31. | 14.71% | — | 19.32% | 19.74% | 13.08% | 40.82% | 49.48% | 23.57% | 1.58% | — | 9.40% | -19.79% | 6.74% |
| 2009. 12. 31. | 17.68% | — | 20.32% | 71.49% | 9.90% | 45.45% | 41.40% | 24.25% | 21.85% | — | 9.59% | -17.10% | 5.51% |
| 2008. 12. 31. | -43.93% | — | 20.58% | 42.86% | 13.43% | -30.76% | 48.43% | 30.46% | 41.63% | — | 14.08% | -19.75% | 6.66% |
| 2007. 12. 31. | 7.96% | — | 17.72% | 20.50% | 15.08% | 21.61% | 46.69% | 24.41% | 18.01% | — | 12.53% | -22.94% | 5.25% |
| 2006. 12. 31. | 3.49% | — | 15.56% | 15.86% | 16.89% | 24.25% | -65.54% | 28.11% | 25.25% | — | 27.10% | -47.24% | 1.21% |
| 2005. 12. 31. | 10.01% | — | 17.96% | 26.77% | 17.67% | 18.34% | 26.88% | 27.49% | 25.85% | — | 12.32% | -83.72% | 7.99% |
보고서 기준: 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
산업 부문과의 비교: 제약, 생명공학 및 생명과학
Celgene Corp., ROE, 장기 추세, 산업 부문과 비교: 제약, 생명공학 및 생명과학
| Celgene Corp. | 제약, 생명공학 및 생명과학 | |
|---|---|---|
| 2018. 12. 31. | 65.67% | 25.64% |
| 2017. 12. 31. | 42.48% | 14.60% |
| 2016. 12. 31. | 30.29% | 22.31% |
| 2015. 12. 31. | 27.07% | 21.69% |
| 2014. 12. 31. | 30.65% | 21.22% |
| 2013. 12. 31. | 25.94% | 20.56% |
| 2012. 12. 31. | 25.57% | 18.37% |
| 2011. 12. 31. | 23.91% | 15.55% |
| 2010. 12. 31. | 14.71% | 14.28% |
| 2009. 12. 31. | 17.68% | 20.65% |
| 2008. 12. 31. | -43.93% | 21.59% |
| 2007. 12. 31. | 7.96% | 17.30% |
| 2006. 12. 31. | 3.49% | 22.03% |
| 2005. 12. 31. | 10.01% | 19.22% |
보고서 기준: 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
업계와의 비교: 의료
Celgene Corp., ROE, 장기 추세, 업계와의 비교: 의료
| Celgene Corp. | 의료 | |
|---|---|---|
| 2018. 12. 31. | 65.67% | 17.33% |
| 2017. 12. 31. | 42.48% | 14.32% |
| 2016. 12. 31. | 30.29% | 17.89% |
| 2015. 12. 31. | 27.07% | 18.18% |
| 2014. 12. 31. | 30.65% | 18.66% |
| 2013. 12. 31. | 25.94% | 18.20% |
| 2012. 12. 31. | 25.57% | 17.48% |
| 2011. 12. 31. | 23.91% | 15.35% |
| 2010. 12. 31. | 14.71% | 14.63% |
| 2009. 12. 31. | 17.68% | 19.52% |
| 2008. 12. 31. | -43.93% | 18.97% |
| 2007. 12. 31. | 7.96% | 17.18% |
| 2006. 12. 31. | 3.49% | 20.41% |
| 2005. 12. 31. | 10.01% | 18.45% |
보고서 기준: 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).